Pemetrexed + Gemcitabine + Platinol
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Transitional Cell
Conditions
Carcinoma, Transitional Cell
Trial Timeline
Dec 1, 2004 → Jul 1, 2006
NCT ID
NCT00101842About Pemetrexed + Gemcitabine + Platinol
Pemetrexed + Gemcitabine + Platinol is a phase 1/2 stage product being developed by Eli Lilly for Carcinoma, Transitional Cell. The current trial status is completed. This product is registered under clinical trial identifier NCT00101842. Target conditions include Carcinoma, Transitional Cell.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00101842 | Phase 1/2 | Completed |
Competing Products
20 competing products in Carcinoma, Transitional Cell